Esmeralda Young
Adult Health · Tampa, FLNPI 1083954465
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,283 of the $13,950 with a category attached, or 66.5%. 34 manufacturers reported payments, led by AbbVie at 28.4% of the total. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $156.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Abbott$3K
- Novo Nordisk$653
- Neurocrine Biosciences, Inc.$627
- AstraZeneca$582
- Sanofi-aventis U.S. LLC$448
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$4,60033%
- Travel & lodging$350%
- Food & beverage$9,28367%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $3,957 |
| Abbott | 9 | $2,923 |
| Novo Nordisk | 7 | $653 |
| Neurocrine Biosciences, Inc. | 5 | $627 |
| AstraZeneca | 5 | $582 |
| Sanofi-aventis U.S. LLC | 4 | $448 |
| GSK | 4 | $379 |
| Teva Pharmaceuticals USA, Inc. | 3 | $366 |
| Bayer | 3 | $330 |
| Dexcom, Inc. | 3 | $326 |
| Sanofi Pasteur Inc. | 3 | $271 |
| Esperion Therapeutics, Inc. | 2 | $246 |
| Amgen | 2 | $234 |
| Corcept Therapeutics | 2 | $223 |
| Johnson & Johnson | 2 | $210 |
| Abiomed | 2 | $198 |
| Madrigal Pharmaceuticals | 1 | $132 |
| Astellas Pharma US Inc | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $123 |
| Boston Scientific | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Axonics, Inc. | 2 | $118 |
| Argenx US, Inc. | 1 | $116 |
| Alkermes, Inc. | 1 | $115 |
| Insulet Corporation | 1 | $114 |
| Xeris Pharmaceuticals, Inc. | 1 | $114 |
| Ascensia Diabetes Care US Inc. | 1 | $112 |
| Gilead | 1 | $103 |
| Boehringer Ingelheim | 1 | $98 |
| Insmed, Inc. | 1 | $89 |
| Lilly USA, LLC | 1 | $83 |
| E.r. Squibb & Sons, L.L.C. | 1 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$2,754
- FREESTYLE LIBRE 3$2,619
- INGREZZA$627
- VRAYLAR$596
- LYBALVI$459
- TZIELD$363
- NURTEC ODT$248
- NEXLIZET$246
- NEXLETOL$246
- AUSTEDO$245
- Kerendia$245
- Wegovy$245
- DEXCOM G7 GSS (161)$243
- AIRSUPRA$243
- FARXIGA$242
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$157
- REZDIFFRA$132
- DEXCOM STELO GLUCOSE BIOSENSOR$130
- Korlym$127
- Veozah$125
How this compares
$13,950 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $40,878 |
| OzempicSemaglutide | 23 | $20,685 |
| EliquisApixaban | 13 | $14,624 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $12,981 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,689 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,914 |
| Novolog FlexpenInsulin Aspart | 16 | $2,192 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $1,563 |
| Atorvastatin Calcium | 176 | $1,105 |
| Ventolin HfaAlbuterol Sulfate | 13 | $893 |
| Diclofenac Sodium | 41 | $842 |
| Omeprazole | 43 | $827 |
| Rosuvastatin Calcium | 45 | $763 |
| Levothyroxine Sodium | 67 | $560 |
| Gabapentin | 44 | $525 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $98 | $40,87835 claims |
| Novo NordiskOzempic | $653 | $20,68523 claims |
| AbbVieSynthroid | $3,957 | $46911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Tampa
- Jamie JohnsonTampa$58K
- Jennifer GodshallTampa$29K
- Michael RoggelinTampa$21K
- Mercedes FernandezTampa$19K
- Cashawna SchlossnagleTampa$18K
- Jennifer BishopTampa$17K
- Meredith ButlerTampa$16K
- Kimberly RandolphTampa$14K
- Peggy WallaceTampa$12K
- Sarah KossiverTampa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.